FDA’s updated guidance on interchangeable biosimilars gets mixed response
Regulatory NewsMary Ellen Schneider
Biologics/ biosimilars/ vaccinesClinical TrialsGuidanceProduct LifecycleUnited StatesRegulatory NewsMary Ellen SchneiderBiologics/ biosimilars/ vaccinesClinical TrialsGuidanceProduct LifecycleUnited States